Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMNE - Thanks to the guy who runs up the tree. I took a 2 bagger on it. I will watch it now.
AHR going again this a.m. Green now and looking for more.
New high today. Lots of interest and the PR blitz is underway.
Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
10:43 am ET 05/07/2009- PR Newswire
NEW YORK, May 7/PRNewswire-FirstCall/ -- Delcath Systems, Inc., (Nasdaq: DCTH)a medical technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment of cancers of the liver, announced today that Eric D. Whitman, MD, Director of the Atlantic Melanoma Center and a Principal Investigator of Delcath's Phase III trial, will present at The 7th World Congress on Melanoma, to be held in Vienna, Austria, May 12-16, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )
Dr. Whitman's presentation, titled Percutaneous Isolated Hepatic Perfusion for Cutaneous and Uveal Metastatic Melanoma, will discuss his experience with the Delcath PHP System(TM), as part of Delcath's multi-center Phase III trial for metastatic melanoma, currently enrolling at twelve leading cancer centers throughout the United States.
This clinical study is testing the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments.
Patients in the Phase III trial are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System(TM) or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), patients are permitted to "cross-over" from the best alternative care arm to receive treatment with the Delcath System at the time of disease progression.
Commenting on Dr. Whitman's upcoming presentation, Richard L. Taney, President and CEO of Delcath Systems, stated, "As we move towards full enrollment of Delcath's pivotal Phase III Metastatic Melanoma Study, increasing the awareness of the Delcath PHP System(TM) and its use for metastatic melanoma becomes of even greater importance. We are excited that Dr. Whitman will be sharing his experience with our System at such a prestigious conference and with such an international attendance. We look forward to more opportunities such as these to continue informing the medical community about the Delcath System."
Ouch. I didn't pull the trigger and look at it run. Still learning
My money is with SQNM right now as a future multi-bagger.
It might come bask some after the open. About 10-Noon. I think there are many making a quick double from .15. I will keep an eye on this. Dreaded RS might occur if they get desperate.
OK just don't like the delisting notice in the news. http://finance.yahoo.com/news/La-Jolla-Pharmaceutical-bw-14886684.html?.v=1
.35 pre-market on LJPC good call. Is it too late?
Big day - good luck.
I find the longer the message board Ibox, the worse the stock. This one included.
Possible multi-bagger - great value now - you can buy at 5 or 7 or 9 as it climbs.
From Motley Fool today...
In search of Bigfoot
Trial lawyers are nothing if not predictable. Thus, when Sequenom announced that the data for its prenatal Down syndrome test couldn't be relied on any longer because of improper actions by employees, causing shares to plummet 75%, observers expected that lawsuits would be filed en masse. The lawyers haven't disappointed.
Shareholders might be sitting on some pretty steep losses right now, having believed -- as everyone else did -- that Sequenom's test was valid, and that it had huge potential for growth once it was released this summer. But the market may have overreacted.
Sequenom's management has indicated that it still believes in the SEQureDx test, but it's not going to release it until two large independent clinical tests are completed, which might not be until the first half of 2010. Those tests could end up confirming the accuracy of the SEQureDx, a test that was seen as just as effective as amniocentesis, but without the risks. The company, once unloved, became a star but is once again suffering from don't-want-itis.
CAPS All-Star member JakilaTheHun admits choosing Sequenom may be questionable, but also says management may be vindicated.
This is a somewhat speculative pick. I believe the market has overreacted to the revelation that Sequenom's Down Syndrome test had flaws due to employee mishandling of data. The stock was worth $15 before that and even that might have been low. Investors regularly overreact to news in the biotech sector and I believe that to be the case here as well. The only thing that gives me pause, however, is that Sequenom's cash situation is not all that great and they are going [to] need more of it at some point. Even if the market is overreacting, that doesn't change the fact that [Sequenom] needs "the market" to sustain itself. We'll see how this plays out, but I'll take a gamble on the long side because risk-reward greatly favors that side.
The good news is that there seems to be a lot of interest at a 3.70 - 3.80 price point right now. Volume is way up so we might not go so low. Motley Fool had a good article on this one today.
Suggestion: Wilf or Captain Billy on Twitter!
Anyone looking at AHR? It's moving good the last couple of days.
How do you think these class action suits will go? Here's my take.....Whaaaah I am down 80% overnight - sue somebody. Why don't they just buy more?
I got some at 3.50 - What's the bounce going to? 7? 10? More?
great news - this outfit is coming along experience-wise.
3.01 high today - hopes of big news coming tonight on a DCTH conference call.
busting out opened near 2.50 and settling at 2.25. I'm green!
Hit 2.00 today!!!
Sneaking up to 2; 3 in the future!
OK thanks. I am looking at ACAS and AGCN based on your notes. I feel a little late to the table.
DCTH, may not be your board's style, but it have been moving on good news lately.
got out at 13.32 from 8. Will watch from sidelines in case it dips again.
I think this is a do or die season. I just read a book about shipwreck hunting in the northeast and it seems that 3 years is about what it takes to get the job done and move on to the next one. Especially if conditions are tough and there is other interest in the area. Good luck crew. The shareholders could use a boost!
Big Day! Need to get more interest here.
9:28AM Delcath: Data Safety Monitoring Board unanimously recommends continuation of Phase III clinical trial for inoperable metastatic melanoma (DCTH) 1.40 : Co announces that the Data and Safety Monitoring Board reviewed clinical data on the first 51 patients enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. After reviewing the data on more than one half of the required patients in this trial, the DSMB unanimously recommended that the trial continue to enroll patients with the goal of reaching the 92 patients required to complete the study. The current eleven participating cancer centers in this trial will continue to evaluate and enroll patients and the DSMB is slated to review updated clinical data following recruitment of the 69th patient, which would mark the 75% enrollment point for this trial.
I'd like to see this one move!
Bottlerocket! The recent jumps make the chart look similar to Oct 07. I remember the day I was green for about 2 hours! Too bad we need a gross of bottlerockets to get back to that level.
Who will hit the ask at .08? Is there any relevant news out there?
Put me down for May 6 at Noon!
No one wanted my 2s on Friday - maybe that's why?
I put some 2s out there. Hope the get hit. It would be nice to see this get to 3
With you - but the best buy on any of these is at .0001 I think.
Is BUNM worth it? It's heating up and closing in on 1 mil subcribers to its music player site. Anyone here on that one?
I posted this about a month ago. My broker has since let me know that it's a 12-month restriction for this one.
Dividend news. I just posted something on the ORRV Board as I got a response from my agent.
- restrictions may be 1-2 years but they are looking into it to be certain (I will keep you posted).
- Broker will charge a fee if I want the certificate broken up.
- no fee to keep the shares in my account
- no market value for ORRV so the breakdown may not even be possible.
Sounds like there will be alot of red tape to cut through.
Ok - Thanks to everyone. Let's hope these shares amount to something in the future!
what makes this go to the lowest value from time to time? I thought it was steady at .04 all week? Any help would be appreciated.
ORRV needs some love. A possible treasure salvage partnership brewing.
OK should be a very interesting day. Is the speculation a wreck that has been in the news recently, or something else.